Hoff, Paulo M <br/><br/>
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Oct 2012 
 - 3596-603 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2012.42.6031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Brazil<br/>Capecitabine<br/>Colorectal Neoplasms--drug therapy<br/>Deoxycytidine--analogs & derivatives<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Fluorouracil--analogs & derivatives<br/>Humans<br/>Infusions, Intravenous<br/>Kaplan-Meier Estimate<br/>Leucovorin--therapeutic use<br/>Male<br/>Middle Aged<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Organoplatinum Compounds--therapeutic use<br/>Prognosis<br/>Proportional Hazards Models<br/>Pyridines--therapeutic use<br/>Quinazolines--therapeutic use<br/>Survival Analysis